AngioDynamics (NASDAQ:ANGO - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of -0.380--0.340 for the period, compared to the consensus estimate of -0.400. The company issued revenue guidance of $282.0 million-$288.0 million, compared to the consensus revenue estimate of $283.9 million. AngioDynamics also updated its FY25 guidance to ($0.38)-($0.34) EPS.
AngioDynamics Price Performance
Shares of ANGO traded up $3.54 during midday trading on Wednesday, hitting $12.94. The stock had a trading volume of 4,421,281 shares, compared to its average volume of 1,328,826. The firm has a market cap of $525.80 million, a price-to-earnings ratio of -2.12 and a beta of 0.59. The company has a 50 day simple moving average of $7.87 and a two-hundred day simple moving average of $7.30. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $13.13.
AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. During the same quarter last year, the firm earned ($0.05) EPS. AngioDynamics's revenue for the quarter was down .1% compared to the same quarter last year. Analysts forecast that AngioDynamics will post -0.41 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on the stock. Canaccord Genuity Group reduced their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, October 4th. HC Wainwright reissued a "buy" rating and set a $14.00 price target on shares of AngioDynamics in a research report on Tuesday, December 10th.
Read Our Latest Analysis on AngioDynamics
About AngioDynamics
(
Get Free Report)
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
Featured Articles
Before you consider AngioDynamics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.
While AngioDynamics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
